<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="issn">2168-8184</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus</publisher-name><publisher-loc>Palo Alto (CA)</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12100672</article-id><article-id pub-id-type="doi">10.7759/cureus.82829</article-id><article-categories><subj-group subj-group-type="heading"><subject>Urology</subject></subj-group><subj-group><subject>Pathology</subject></subj-group><subj-group><subject>Orthopedics</subject></subj-group></article-categories><title-group><article-title>Ewing Sarcoma Family of Tumors (ESFTs) of Renal Origin Presenting With Bone Metastases: A Case Report</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Muacevic</surname><given-names>Alexander</given-names></name></contrib><contrib contrib-type="editor"><name><surname>Adler</surname><given-names>John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Jakowczuk</surname><given-names>Tiffany E</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Gord G</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Tomaszewski</surname><given-names>Jeffrey J</given-names></name><xref rid="aff-3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Tae Won</given-names></name><xref rid="aff-4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Zeffren</surname><given-names>Marc</given-names></name><xref rid="aff-3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Obiora</surname><given-names>Daisy C</given-names></name><xref rid="aff-3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Barshay</surname><given-names>Veniamin</given-names></name><xref rid="aff-5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Edmonston</surname><given-names>Tina B</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Shojaei</surname><given-names>Hadi</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Birbe</surname><given-names>Ruth</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Cooper Medical School, Rowan University, Camden, USA </aff><aff id="aff-2">
<label>2</label>
Pathology, Cooper University Hospital, Camden, USA </aff><aff id="aff-3">
<label>3</label>
Urology, Cooper University Hospital, Camden, USA </aff><aff id="aff-4">
<label>4</label>
Orthopedics, Cooper University Hospital, Camden, USA </aff><aff id="aff-5">
<label>5</label>
Radiology, Cooper University Hospital, Camden, USA </aff><author-notes><corresp id="cor1">
Ruth Birbe <email>birbe-ruth@cooperhealth.edu</email>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>23</day><month>4</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>4</month><year>2025</year></pub-date><volume>17</volume><issue>4</issue><elocation-id>e82829</elocation-id><history><date date-type="accepted"><day>23</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025, Jakowczuk et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Jakowczuk et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xlink:href="https://www.cureus.com/articles/355832-ewing-sarcoma-family-of-tumors-esfts-of-renal-origin-presenting-with-bone-metastases-a-case-report">This article is available from https://www.cureus.com/articles/355832-ewing-sarcoma-family-of-tumors-esfts-of-renal-origin-presenting-with-bone-metastases-a-case-report</self-uri><abstract><p>We report a unique case of a female patient in her fifth decade of life who presented with groin pain and was found to have a right kidney mass measuring approximately 8 cm, in addition to multiple bone metastases. Both the nephrectomy specimen and the bone biopsy were found to belong to the Ewing sarcoma family of tumors (ESFTs). This was confirmed by immunohistochemical studies and fluorescence in situ hybridization (FISH) showing <italic>EWSR1</italic> gene rearrangement. Molecular analysis with next-generation sequencing (NGS) showed a type II <italic>EWSR1:FLI1</italic> gene fusion. The patient&#x02019;s disease progressed rapidly, and she passed away approximately three months after admission. Although extremely rare in the kidney, ESFT should be considered in patients who present with clinically aggressive kidney tumors.</p></abstract><kwd-group kwd-group-type="author"><kwd>ewing sarcoma (es)</kwd><kwd>ewing sarcoma family of tumors(esft)</kwd><kwd>ewing sarcoma of the kidney</kwd><kwd>extra-skeletal ewing sarcoma</kwd><kwd>fluorescence in situ hybridization (fish)</kwd><kwd>metastatic renal cancer</kwd><kwd>next generation sequencing (ngs)</kwd><kwd>res: renal ewing sarcoma</kwd><kwd>urologic neoplasms</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Ewing sarcoma family of tumors (ESFTs), which includes Ewing sarcoma and primitive neuroectodermal tumors (PNETs), is a group of aggressive malignant neoplasms characterized by small round blue cells and fusion of the &#x0200b;&#x0200b;&#x0200b;&#x0200b;&#x0200b;&#x0200b;<italic>EWSR1</italic> gene with other genes such as <italic>FLI1</italic> and&#x000a0;<italic>ERG&#x000a0;</italic>[<xref rid="REF1" ref-type="bibr">1</xref>]. ESFT of renal origin behaves more aggressively than those arising in other sites, including bone [<xref rid="REF2" ref-type="bibr">2</xref>-<xref rid="REF6" ref-type="bibr">6</xref>]. Up&#x000a0;to 50% of patients present with metastasis, and only 50% of those survive after five years [<xref rid="REF2" ref-type="bibr">2</xref>-<xref rid="REF3" ref-type="bibr">3</xref>].</p></sec><sec sec-type="cases"><title>Case presentation</title><p>A&#x000a0;woman in her fifth decade of life with a history of diabetes and nephrolithiasis presented with groin pain. Computed tomography (CT) imaging of the pelvis revealed a 7.8 cm centrally necrotic, hypovascular right renal mass (Figure <xref rid="FIG1" ref-type="fig">1</xref>). Magnetic resonance imaging (MRI) and a nuclear bone scan showed multiple bone lesions involving the right femur, ribs, iliac bone, and clavicle. MRI of the femur lesion is shown in Figure <xref rid="FIG2" ref-type="fig">2</xref>. Biopsy of the involved femur revealed a small round blue cell tumor with crush artifact (Figure <xref rid="FIG2" ref-type="fig">2</xref>). Immunohistochemical studies demonstrated positive CD99, synaptophysin, and NKX2.2. The Ki-67 proliferation index was 80%, and fluorescence in situ hybridization (FISH) analysis showed&#x000a0;EWSR1&#x000a0;gene rearrangement. A robotic-assisted laparoscopic radical nephrectomy produced an 8.5 cm lobulated, solid, tan tumor that extended into the pelvic mucosa and perinephric fat. Histologically, the tumor comprised monomorphic small round blue cells with rosettes, necrosis, and a high mitotic count (20 mitoses per 10 high-power fields). The immunoprofile of the renal tumor resembled that of the bone biopsy (Figure <xref rid="FIG1" ref-type="fig">1</xref>). Thus, the pathologic stage was pT2, pNx, pM1 (bone), with a histologic grade of 3 (French Federation of Cancer Centers Sarcoma Group). Based on these findings, a diagnosis of renal ESFT was made. Next-generation sequencing (NGS) molecular analysis of the kidney tumor showed a type II<italic>&#x000a0;EWSR1:FLI1</italic>&#x000a0;gene fusion between exon 7 of&#x000a0;<italic>EWSR1</italic>&#x000a0;and exon 5 of&#x000a0;<italic>FLI1</italic>&#x000a0;(Figure <xref rid="FIG3" ref-type="fig">3</xref>). The patient experienced a complicated postoperative course and rapid disease progression, including pathologic fractures, sepsis, additional bone metastases, and retroperitoneal lymphadenopathy. After electing hospice care, she expired approximately three months after admission.</p><fig position="anchor" fig-type="figure" id="FIG1"><label>Figure 1</label><caption><title>Right renal mass.</title><p>Computed tomography (CT): coronal (A) and axial (B), with area of interest identified by arrows. Pathology of nephrectomy: hematoxylin and eosin (H&#x00026;E) stain at 100x (C), 400x (D), and 600x (E). Immunohistochemical stains positive for CD99 (F), synaptophysin (G), and Ki-67 with a high proliferation index between 80% and 90% (H).</p></caption><graphic xlink:href="cureus-0017-00000082829-i01" position="float"/></fig><fig position="anchor" fig-type="figure" id="FIG2"><label>Figure 2</label><caption><title>Right femur lesion.</title><p>Pathology of bone biopsy: hematoxylin and eosin (H&#x00026;E) at 200x (A). Immunohistochemical stains positive for CD99 (B), synaptophysin (C), and Ki67 with a high proliferation index (D). Magnetic resonance imaging (MRI): T1 fat-saturated before (E) and after (F) contrast, sagittal view, with area of interest identified by arrows.</p></caption><graphic xlink:href="cureus-0017-00000082829-i02" position="float"/></fig><fig position="anchor" fig-type="figure" id="FIG3"><label>Figure 3</label><caption><title>Next-generation sequencing (NGS) of the kidney tumor demonstrating a type II fusion of exon 7 of EWSR1 with exon 5 of FLI1.</title></caption><graphic xlink:href="cureus-0017-00000082829-i03" position="float"/></fig><p>Review of the patient&#x02019;s electronic medical record revealed numerous prior CT scans of the abdomen and pelvis as early as eight years before presentation. Most appeared to be without contrast, presumably for evaluation of her known history of nephrolithiasis. Approximately four years before presentation, she underwent renal ultrasound (RUS), during which a questionable 4.8 cm right lateral midpole mass versus prominent renal tissue was noted, with no further workup per chart review. A chest radiograph in the month before presentation was unremarkable, and a hip radiograph in the days leading up to presentation showed only an 8 mm intertrochanteric cyst in the right femur.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Extraskeletal ESFTs, which represent&#x000a0;up to 30% of all cases of ESFT [<xref rid="REF7" ref-type="bibr">7</xref>], were first described in 1975 by Angervall and Enzinger [<xref rid="REF8" ref-type="bibr">8</xref>]. In contrast to skeletal ESFT, which most commonly affects males in the second decade of life [<xref rid="REF9" ref-type="bibr">9</xref>], patients with extraskeletal ESFT are more often female and tend to be older [<xref rid="REF7" ref-type="bibr">7</xref>,<xref rid="REF10" ref-type="bibr">10</xref>]. However, current literature suggests that the demographics of patients with renal ESFT seem to match more closely with those of skeletal ESFT [<xref rid="REF2" ref-type="bibr">2</xref>-<xref rid="REF5" ref-type="bibr">5</xref>], making this case presentation even rarer. Overall survival of patients with extraskeletal ESFT can be worse in the first two years compared to patients with skeletal ESFT. After two years, patients with skeletal ESFT exhibit lower overall survival [<xref rid="REF7" ref-type="bibr">7</xref>].</p><p>Mor et&#x000a0;al. were the first to describe ESFT of renal origin in 1994, at which time peripheral PNETs were already regarded as aggressive neoplasms with early metastasis to other sites such as bone [<xref rid="REF6" ref-type="bibr">6</xref>]. More recent studies found that nearly half of all patients with renal ESFT had distant metastasis at presentation [<xref rid="REF2" ref-type="bibr">2</xref>-<xref rid="REF5" ref-type="bibr">5</xref>]. Bone metastases occur in up to 15% of patients with advanced-stage renal tumors within the first year of diagnosis [<xref rid="REF11" ref-type="bibr">11</xref>], whereas primary malignant Ewing sarcoma accounts for fewer than 0.2% of all cancers diagnosed in the United States [<xref rid="REF12" ref-type="bibr">12</xref>].</p><p>Symptoms of renal ESFT are nonspecific, initially leading clinicians to consider more common neoplasms [<xref rid="REF2" ref-type="bibr">2</xref>-<xref rid="REF4" ref-type="bibr">4</xref>]. Due to the rarity of primary renal ESFT, there is currently no standardized protocol for treating this entity [<xref rid="REF2" ref-type="bibr">2</xref>-<xref rid="REF4" ref-type="bibr">4</xref>]. The association between nephrolithiasis and renal ESFT has not yet been elucidated. A 2015 meta-analysis demonstrated an increased risk of other renal cancers in patients with kidney stones, but only in male patients [<xref rid="REF13" ref-type="bibr">13</xref>].</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>While ESFTs are most commonly known to affect the bones, extraskeletal ESFTs have been reported and are often more aggressive. Along with evidence from existing literature, the presence of a sizable renal lesion four years before presentation supports the diagnosis of primary renal ESFT in our patient. This case adds to the body of knowledge on renal ESFTs and confirms their aggressive behavior.</p></sec></body><back><fn-group content-type="conflict"><title>Disclosures</title><fn fn-type="COI-statement"><p><bold>Human subjects:</bold> Consent for treatment and open access publication was obtained or waived by all participants in this study.</p><p><bold>Conflicts of interest:</bold> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p><p><bold>Payment/services info:</bold> All authors have declared that no financial support was received from any organization for the submitted work.</p><p><bold>Financial relationships:</bold> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p><p><bold>Other relationships:</bold> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p></fn></fn-group><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>&#x000a0; Tiffany E. Jakowczuk, Ruth Birbe</p><p><bold>Drafting of the manuscript:</bold>&#x000a0; Tiffany E. Jakowczuk, Ruth Birbe</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>&#x000a0; Gord G. Zhu, Jeffrey J. Tomaszewski, Tae Won Kim, Marc Zeffren, Daisy C. Obiora, Veniamin Barshay, Tina B. Edmonston, Hadi Shojaei, Ruth Birbe</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>&#x000a0; Gord G. Zhu, Jeffrey J. Tomaszewski, Tae Won Kim, Marc Zeffren, Daisy C. Obiora, Veniamin Barshay, Tina B. Edmonston, Hadi Shojaei, Ruth Birbe</p><p><bold>Supervision:</bold>&#x000a0; Ruth Birbe</p></fn></fn-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>Molecular cytogenetic characterization of two established ESFT cell lines</article-title><source>Hum Cell</source><person-group>
<name><surname>Ishiguro</surname><given-names>M</given-names></name>
<name><surname>Yuki</surname><given-names>M</given-names></name>
<name><surname>Fukushige</surname><given-names>T</given-names></name>
<name><surname>Mizoguchi</surname><given-names>M</given-names></name>
<name><surname>Kaneko</surname><given-names>Y</given-names></name>
<name><surname>Morishige</surname><given-names>T</given-names></name>
<name><surname>Iwasaki</surname><given-names>H</given-names></name>
</person-group><fpage>41</fpage><lpage>48</lpage><volume>30</volume><year>2017</year><pub-id pub-id-type="pmid">27613543</pub-id>
</element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Extraosseous Ewing's sarcoma/peripheral primitive neuroectodermal tumour of the kidney: a case report and literature review</article-title><source>BMC Urol</source><person-group>
<name><surname>Li</surname><given-names>J</given-names></name>
<name><surname>Nie</surname><given-names>F</given-names></name>
<name><surname>Li</surname><given-names>Y</given-names></name>
</person-group><fpage>197</fpage><volume>22</volume><year>2022</year><pub-id pub-id-type="pmid">36451163</pub-id>
</element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Renal Ewing's sarcoma/primitive neuroectodermal tumor (PNET): a case series of 7 patients and literature review</article-title><source>Transl Androl Urol</source><person-group>
<name><surname>Liang</surname><given-names>L</given-names></name>
<name><surname>Song</surname><given-names>H</given-names></name>
<name><surname>Ma</surname><given-names>B</given-names></name>
<etal/>
</person-group><fpage>548</fpage><lpage>554</lpage><volume>10</volume><year>2021</year><pub-id pub-id-type="pmid">33718057</pub-id>
</element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Ewing sarcoma of the kidney: case series and literature review of an often overlooked entity in the diagnosis of primary renal tumors</article-title><source>Urology</source><person-group>
<name><surname>Rowe</surname><given-names>RG</given-names></name>
<name><surname>Thomas</surname><given-names>DG</given-names></name>
<name><surname>Schuetze</surname><given-names>SM</given-names></name>
<name><surname>Hafez</surname><given-names>KS</given-names></name>
<name><surname>Lawlor</surname><given-names>ER</given-names></name>
<name><surname>Chugh</surname><given-names>R</given-names></name>
</person-group><fpage>347</fpage><lpage>353</lpage><volume>81</volume><year>2013</year><pub-id pub-id-type="pmid">23374800</pub-id>
</element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Primary Ewing sarcoma/primitive neuroectodermal tumor of the kidney: the MD Anderson Cancer Center experience</article-title><source>Cancers (Basel)</source><person-group>
<name><surname>Tarek</surname><given-names>N</given-names></name>
<name><surname>Said</surname><given-names>R</given-names></name>
<name><surname>Andersen</surname><given-names>CR</given-names></name>
<etal/>
</person-group><volume>12</volume><year>2020</year></element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Malignant peripheral primitive neuroectodermal tumor (PNET) of the kidney</article-title><source>Med Pediatr Oncol</source><person-group>
<name><surname>Mor</surname><given-names>Y</given-names></name>
<name><surname>Nass</surname><given-names>D</given-names></name>
<name><surname>Raviv</surname><given-names>G</given-names></name>
<name><surname>Neumann</surname><given-names>Y</given-names></name>
<name><surname>Nativ</surname><given-names>O</given-names></name>
<name><surname>Goldwasser</surname><given-names>B</given-names></name>
</person-group><fpage>437</fpage><lpage>440</lpage><volume>23</volume><year>1994</year><pub-id pub-id-type="pmid">8084311</pub-id>
</element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Clinical features and outcomes in patients with extraskeletal Ewing sarcoma</article-title><source>Cancer</source><person-group>
<name><surname>Applebaum</surname><given-names>MA</given-names></name>
<name><surname>Worch</surname><given-names>J</given-names></name>
<name><surname>Matthay</surname><given-names>KK</given-names></name>
<name><surname>Goldsby</surname><given-names>R</given-names></name>
<name><surname>Neuhaus</surname><given-names>J</given-names></name>
<name><surname>West</surname><given-names>DC</given-names></name>
<name><surname>Dubois</surname><given-names>SG</given-names></name>
</person-group><fpage>3027</fpage><lpage>3032</lpage><volume>117</volume><year>2011</year><pub-id pub-id-type="pmid">21692057</pub-id>
</element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Extraskeletal neoplasm resembling Ewing&#x02019;s sarcoma</article-title><source>Cancer</source><person-group>
<name><surname>Angervall</surname><given-names>L</given-names></name>
<name><surname>Enzinger</surname><given-names>F</given-names></name>
</person-group><fpage>240</fpage><lpage>251</lpage><volume>36</volume><year>1975</year><pub-id pub-id-type="pmid">1203852</pub-id>
</element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>Ewing sarcoma</article-title><source>Semin Diagn Pathol</source><person-group>
<name><surname>Choi</surname><given-names>EY</given-names></name>
<name><surname>Gardner</surname><given-names>JM</given-names></name>
<name><surname>Lucas</surname><given-names>DR</given-names></name>
<name><surname>McHugh</surname><given-names>JB</given-names></name>
<name><surname>Patel</surname><given-names>RM</given-names></name>
</person-group><fpage>39</fpage><lpage>47</lpage><volume>31</volume><year>2014</year><pub-id pub-id-type="pmid">24680181</pub-id>
</element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>Extraskeletal versus skeletal Ewing sarcoma in the adult population: controversies in care</article-title><source>Surg Oncol</source><person-group>
<name><surname>Lynch</surname><given-names>AD</given-names></name>
<name><surname>Gani</surname><given-names>F</given-names></name>
<name><surname>Meyer</surname><given-names>CF</given-names></name>
<name><surname>Morris</surname><given-names>CD</given-names></name>
<name><surname>Ahuja</surname><given-names>N</given-names></name>
<name><surname>Johnston</surname><given-names>FM</given-names></name>
</person-group><fpage>373</fpage><lpage>379</lpage><volume>27</volume><year>2018</year><pub-id pub-id-type="pmid">30217290</pub-id>
</element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States</article-title><source>BMC Cancer</source><person-group>
<name><surname>Hernandez</surname><given-names>RK</given-names></name>
<name><surname>Wade</surname><given-names>SW</given-names></name>
<name><surname>Reich</surname><given-names>A</given-names></name>
<name><surname>Pirolli</surname><given-names>M</given-names></name>
<name><surname>Liede</surname><given-names>A</given-names></name>
<name><surname>Lyman</surname><given-names>GH</given-names></name>
</person-group><fpage>44</fpage><volume>18</volume><year>2018</year><pub-id pub-id-type="pmid">29306325</pub-id>
</element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>Primary malignant bone tumors--recent developments</article-title><source>Semin Diagn Pathol</source><person-group>
<name><surname>Hameed</surname><given-names>M</given-names></name>
<name><surname>Dorfman</surname><given-names>H</given-names></name>
</person-group><fpage>86</fpage><lpage>101</lpage><volume>28</volume><year>2011</year><pub-id pub-id-type="pmid">21675380</pub-id>
</element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>The risk of kidney cancer in patients with kidney stones: a systematic review and meta-analysis</article-title><source>QJM</source><person-group>
<name><surname>Cheungpasitporn</surname><given-names>W</given-names></name>
<name><surname>Thongprayoon</surname><given-names>C</given-names></name>
<name><surname>O'Corragain</surname><given-names>OA</given-names></name>
<name><surname>Edmonds</surname><given-names>PJ</given-names></name>
<name><surname>Ungprasert</surname><given-names>P</given-names></name>
<name><surname>Kittanamongkolchai</surname><given-names>W</given-names></name>
<name><surname>Erickson</surname><given-names>SB</given-names></name>
</person-group><fpage>205</fpage><lpage>212</lpage><volume>108</volume><year>2015</year><pub-id pub-id-type="pmid">25208892</pub-id>
</element-citation></ref></ref-list></back></article>